gemcitabine has been researched along with ly-2157299 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benhadji, KA; Fujii, H; Ikeda, M; Kondo, S; Lahn, MMF; Ogasawara, K; Takahashi, H; Ueno, H | 1 |
| Benhadji, KA; Blunt, A; Cleverly, A; Deplanque, G; Estrem, ST; Fuchs, M; Garcia-Carbonero, R; Gueorguieva, I; Kozloff, M; Lahn, MMF; Macarulla, T; Melisi, D; Oettle, H; Pezet, D; Smith, C; Tabernero, J; Trojan, J | 1 |
| Benhadji, KA; Cleverly, A; Deplanque, G; Driscoll, KE; Estrem, ST; Fuchs, M; Garcia-Carbonero, R; Kozloff, M; Lahn, MMF; Macarulla, T; Man, M; Melisi, D; Pezet, D; Simionato, F; Smith, C; Tabernero, J; Trojan, J; Wang, S | 1 |
| Benhadji, KA; Cleverly, A; Gueorguieva, I; Lahn, MM; Macarulla, T; Melisi, D; Merz, V; Miles, C; Tabernero, J; Waterhouse, TH | 1 |
1 review(s) available for gemcitabine and ly-2157299
| Article | Year |
|---|---|
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2019 |
3 trial(s) available for gemcitabine and ly-2157299
| Article | Year |
|---|---|
Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinolines | 2017 |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Pyrazoles; Quinolines; Signal Transduction; Transforming Growth Factor beta | 2018 |
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Inflammation; Male; MicroRNAs; Pancreatic Neoplasms; Prognosis; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Survival Rate | 2019 |